WGU D345 Psychopharmacology Master Set 2026/2027 | 400+ Questions & Answers | Antidepressants, Antipsychotics, Mood Stabilizers & ADHD – Western Governors University

This WGU D345 Psychopharmacology Master Set 2026/2027 is an extensive 88-page exam-preparation resource containing 400+ questions, answers, rationales, clinical pearls, and exam tips. It provides comprehensive coverage of psychopharmacology fundamentals and psychiatric medication management, including pharmacodynamics, pharmacokinetics, ADME, receptor pharmacology, neurotransmitters, dopamine pathways, CYP450 interactions, half-life, steady state, pharmacogenomics, antidepressants, antipsychotics, mood stabilizers, anxiolytics, sedative-hypnotics, ADHD medications, adverse reactions, drug interactions, and safe prescribing principles. The document is specifically labeled as a WGU D345 master set for the 2026/2027 exam period. The opening section establishes the pharmacology foundation students need for later clinical questions. It distinguishes pharmacodynamics from pharmacokinetics, reviews absorption, distribution, metabolism, and excretion, and explains agonists, antagonists, partial agonists, receptor affinity, selectivity, potency, efficacy, bioavailability, protein binding, first-pass metabolism, therapeutic index, and volume of distribution. Neurotransmitter content includes dopamine, serotonin, norepinephrine, acetylcholine, GABA, and glutamate, together with the mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular dopamine pathways. CYP3A4, CYP2D6, and CYP1A2 interactions are incorporated into medication-management questions. A substantial section addresses antidepressant pharmacology, including SSRIs, SNRIs, bupropion, mirtazapine, trazodone, vilazodone, vortioxetine, tricyclic antidepressants, and MAO inhibitors. Questions examine mechanisms of action, medication selection, CYP interactions, sexual dysfunction, discontinuation syndrome and the FINISH mnemonic, serotonin syndrome, QT prolongation, seizure risk, TCA overdose, tyramine restrictions, hypertensive crisis, and matching antidepressants to individual clinical presentations. The antipsychotic section compares first- and second-generation agents and covers D2 antagonism, 5-HT2A antagonism, dopamine partial agonism, positive and negative schizophrenia symptoms, extrapyramidal symptoms, acute dystonia, pseudoparkinsonism, akathisia, tardive dyskinesia, VMAT2 inhibitors, neuroleptic malignant syndrome, metabolic syndrome, hyperprolactinemia, QT prolongation, and long-acting injectable antipsychotics. High-yield medications include haloperidol, clozapine, olanzapine, risperidone, paliperidone, quetiapine, ziprasidone, lurasidone, aripiprazole, brexpiprazole, and cariprazine. The master set also provides detailed preparation on bipolar disorder and mood stabilizers, particularly lithium, valproate, carbamazepine, and lamotrigine. Students review lithium monitoring and toxicity, mixed features, rapid cycling, medication interactions, teratogenicity, HLA-B*1502 and Stevens-Johnson syndrome risk, lamotrigine titration, and the risks associated with antidepressant monotherapy in Bipolar I disorder. Anxiety, insomnia, and ADHD pharmacotherapy receive dedicated coverage. The material reviews benzodiazepines, buspirone, propranolol, hydroxyzine, Z-drugs, ramelteon, orexin antagonists, and CBT-I, including benzodiazepine withdrawal and the LOT mnemonic for lorazepam, oxazepam, and temazepam. ADHD content includes methylphenidate, dexmethylphenidate, mixed amphetamine salts, dextroamphetamine, lisdexamfetamine, atomoxetine, stimulant mechanisms, adverse effects, cardiovascular monitoring, and misuse precautions. Later sections emphasize clinical psychopharmacology and safe prescribing, including medication adherence, therapeutic alliance, shared decision-making, treatment-resistant depression, drug-drug interactions, OTC medications and supplements, pregnancy and lactation considerations, older-adult prescribing, treatment monitoring, informed consent, pseudo-resistance, medication tapering, and emergency recognition of severe adverse reactions. The document repeatedly emphasizes an exam strategy of connecting mechanism → adverse effects → monitoring → patient safety. Referenced Academic/Professional Material: The document repeatedly identifies material as “Stahl Pearl,” “Stahl Master Tip,” “Carlat Pearl,” and “Carlat Medication Fact Book Bottom Line.” These references indicate that the study set draws conceptually on Stephen M. Stahl's psychopharmacology resources and The Carlat Medication Fact Book, particularly for mechanisms of action, medication selection, adverse effects, interactions, and clinical prescribing pearls. Because the uploaded document does not supply a complete edition-specific bibliography, an exact edition or journal citation should not be invented. Relevant Students: This master set is particularly relevant to WGU D345 students, Western Governors University students, psychiatric and mental-health nursing students, psychopharmacology students, PMHNP students, MSN and DNP students, advanced practice nursing students, graduate nursing students, and learners reviewing psychiatric medication management, adverse effects, monitoring, and clinical prescribing principles. Its repeated D345-specific tips and OA-focused exam strategies make it especially useful for students preparing for the WGU D345 Objective Assessment (OA). Keywords: WGU D345, WGU D345 Psychopharmacology, WGU D345 Master Set, WGU D345 exam 2026, WGU D345 exam 2027, WGU D345 questions and answers, WGU D345 study guide, WGU D345 OA, D345 Objective Assessment, D345 psychopharmacology questions, Western Governors University D345, psychopharmacology exam, psychopharmacology questions and answers, psychiatric pharmacology, pharmacodynamics, pharmacokinetics, ADME, CYP450 interactions, CYP3A4, CYP2D6, CYP1A2, dopamine pathways, serotonin, norepinephrine, GABA, glutamate, antidepressants, SSRIs, SNRIs, bupropion, mirtazapine, trazodone, TCAs, MAOIs, serotonin syndrome, antidepressant discontinuation syndrome, antipsychotics, first generation antipsychotics, second generation antipsychotics, extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, clozapine, aripiprazole, metabolic syndrome, mood stabilizers, lithium, lithium toxicity, valproate, carbamazepine, lamotrigine, bipolar disorder pharmacology, benzodiazepines, anxiolytics, sedative hypnotics, ADHD medications, stimulants, methylphenidate, amphetamine, lisdexamfetamine, atomoxetine, psychiatric medication monitoring, psychotropic drug interactions, Stahl psychopharmacology, Carlat Medication Fact Book, PMHNP psychopharmacology, WGU exam preparation